Aptose Biosciences (APTO) shareholders approve 2025 auditor choice

Rhea-AI Filing Summary

Aptose Biosciences Inc. held its reconvened Annual and Special Meeting of shareholders on August 22, 2025, where investors voted on corporate matters. Shareholders approved the appointment of the Corporation’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 1,436,464 votes for (96.95%), 36,817 votes against (2.48%), 8,376 abstentions, and 2 broker non-votes. The company also furnished a press release as Exhibit 99.1 providing additional information, which is treated as furnished rather than filed for securities law purposes.

False000088236100008823612025-08-222025-08-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 22, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 22, 2025, Aptose Biosciences Inc., or the “Corporation,” held its reconvened Annual and Special Meeting of the shareholders of the Corporation (the “Meeting”). At the Meeting, shareholders voted in favor of all items of business, as indicated below:

Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm

The Corporation’s shareholders voted to approve the appointment of an independent registered public accounting firm of the Corporation for the fiscal year ended December 31, 2025.

Votes For	% Votes For	Vote Against	% Votes Against	Abstain	Broker Non-Votes
1,436,464	96.95	36,817	2.48	8,376	2

Item 7.01. Regulation FD Disclosure.

On August 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press Release dated August 22, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: August 25, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose Biosciences (APTO) report in this 8-K?

The company reported the results of its reconvened Annual and Special Meeting held on August 22, 2025, where shareholders voted on corporate matters and approved the auditor appointment for the 2025 fiscal year.

What was the main proposal voted on at Aptose Biosciences' August 22, 2025 meeting?

The primary disclosed item was Proposal No. 2, where shareholders voted on the appointment of the Corporation’s independent registered public accounting firm for the fiscal year ended December 31, 2025.

How did Aptose Biosciences shareholders vote on the 2025 auditor appointment?

Shareholders voted 1,436,464 shares for (96.95%), 36,817 shares against (2.48%), and 8,376 shares abstaining, with 2 broker non-votes, approving the appointment of the independent registered public accounting firm.

Did Aptose Biosciences provide any additional disclosure with this 8-K?

Yes, the company furnished a press release dated August 22, 2025 as Exhibit 99.1, which is incorporated by reference but is deemed furnished, not filed, for purposes of the Securities Exchange Act of 1934.

What is the significance of the information being 'furnished' rather than 'filed' by Aptose Biosciences?

The company states that the information in the Exhibit 99.1 press release is furnished under Regulation FD and is not deemed filed for Section 18 liability under the Exchange Act, nor automatically incorporated into Securities Act or Exchange Act filings.

Who signed the Aptose Biosciences 8-K related to the August 22, 2025 meeting?

The report was signed on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D., who serves as Chairman, President, and Chief Executive Officer.